An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Sapanisertib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; Breast cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 21 Sep 2016 Status changed from not yet recruiting to recruiting.
- 28 Jan 2015 New trial record